New therapy for triple negative breast cancer

May 25, 2020

This type of TNBC tumor does not express any of the receptors involved in most breast cancers (estrogen, progesterone and HER2), so the most common treatments, such as the hormone therapy, are not viable in these patients.

This new study is led by Mar Orzáez, principal researcher at the Laboratory of Peptide and Protein Chemistry at CIPF, and Ramón Martínez Máñez, member of the CIPF-UPV Joint Research Unit of Diseases Mechanisms and Nanomedicine, and research at the Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM) of the UPV and at the Centro de Investigación Biomédica en Red (CIBER) in the subject area of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). The study proves that a combined treatment of a senescence inducer and a senolytic nanoparticle selectively removes senescent cells, delays tumor growth and reduces metastasis in a model of aggressive breast cancer.

The application of senescence inducers has represented a successful strategy for treating breast cancer patients thus far, although the accumulation of senescent cells in the body can favor relapse of the tumor.

Senescence or cell aging occurs both in physiological and pathological situations. When a cell enters into senescence, it stops dividing and releases substances that cause inflammation.

When an uncontrolled accumulation of those senescent cells happens, the excess of inflammatory factors can eventually damage healthy cells, thus favoring aging and the appearance of disorders such as diabetes and neurodegenerative diseases, as well as fostering the developing of tumors and causing metastasis.

With this new approach, after inducing senescence, cells are removed through the treatment with a senolytic nanoparticle. This opens a new therapeutic opportunity to improve results with breast cancer patients and establishes a new combined treatment that can be significant for other senescence-inducing chemotherapy drugs.

The results, published in the Journal of Controlled Release (JCR), provide new therapeutic methodologies to be developed in subsequent stages and clinical trials. Moreover, they can address several types of tumor.

Orzáez and Máñez have explained that "the senescence induction in tumors represents an advance in cancer treatment, which may be even greater in combination with this type of senolytic treatments that remove senescent cells and help to reduce metastasis."
-end-
Manuel Serrano, researcher at the Institute for Research in Biomedicine (IRB) of Barcelona, also participated in the study.

Universitat Politècnica de València

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.